News Release

Suven Life Sciences to Present Ropanicant Baseline data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference, Miami, USA.

HYDERABAD, INDIA (28-May-2024), Suven Life Sciences, a clinical-stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, announced its participation and scientific presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, USA during May 28 - 31, 2024.

The ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information.

Suven Scientific Presentations at ASCP:

1. Ropanicant (SUVN-911), an α4β2 Receptor Antagonist: A Phase-2 Study Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder (**W91, Wednesday, May 29, 2024**).

2. Effect of Ropanicant (SUVN-911), an α4β2 Receptor Antagonist in Animal Models of Depression (**T92, Thursday, May 30, 2024**).

W91 presentation will include baseline data of currently ongoing Phase-2 study evaluating the safety and efficacy in participants with moderate to severe major depressive disorder. T92 presentation covers details of effect of ropanicant in animal models of depression.

About Ropanicant (SUVN-911) Phase-2 Study: The Phase-2 study evaluates the safety and efficacy of ropanicant in major depressive disorder patients (ClinicalTrials.gov Identifier: NCT06126497). The study will recruit and randomize approximately 36 patients in the ratio of 1:1:1 to Ropanicant 45 mg qd, ropanicant 30 mg bid, or ropanicant 45 mg bid treatment groups. Ropanicant effects on the depressive symptoms will be followed using the Montgomery-Åsberg Depression Rating Scale (MADRS) score. The total study duration is 21 days. The study is being conducted in the USA.

About Ropanicant (SUVN-911): Ropanicant is a novel, potent and selective α4β2 nAChR antagonist. It has excellent ADME properties like oral bioavailability and brain penetration, and no drug-drug interaction liability. Ropanicant has shown robust efficacy in various animal models of depression. The efficacy in animal models was in conjunction with an increase in serotonin levels in prefrontal cortex. It does not act like conventional SSRIs i.e., efficacy onset is faster than SSRIs (most likely acts by enhancing the release of monoamine neurotransmitters). Ropanicant addresses major limitations of current depressive disorder therapeutics by offering rapid onset of action, does not cause sexual dysfunction and shows pro-cognitive effects. Pre-clinical in-vitro and in-vivo efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and Phase-1 studies in healthy subjects under US IND have been successfully completed for ropanicant.

About Suven Life Sciences ("Suven"): Suven Life Sciences Limited (Suven) is focused on discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (phase-2 study completed; pivotal phase-3 study in planning); Ropanicant (SUVN-911) for MDD (phase-2 study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (phase-2 study in planning), SUVN-I6107 for dementia in PD (phase-1 study in planning) and 2 other compounds in early stages of clinical development. In addition to these clinical assets, we have 6 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information please visit our website at http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time*